A recent study indicates that a new class of oral diabetes drugs may help protect patients’ kidney health in addition to lowering their blood sugar levels. The findings appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Agents that inhibit the sodium-glucose cotransporter 2 (SGLT2) in the kidney lower blood sugar by augmenting excretion of glucose in the urine. In addition, this new class of anti-diabetes medication lowers blood pressure and body weight. The effects of SGLT2 inhibitors on kidney function have not been thoroughly assessed, however.
